Literature DB >> 11919254

DNA microarrays in clinical oncology.

Sridhar Ramaswamy1, Todd R Golub.   

Abstract

Aberrant gene expression is critical for tumor initiation and progression. However, we lack a comprehensive understanding of all genes that are aberrantly expressed in human cancer. Recently, DNA microarrays have been used to obtain global views of human cancer gene expression and to identify genetic markers that might be important for diagnosis and therapy. We review clinical applications of these novel tools, discuss some important recent studies, identify promising avenues of research in this emerging field of study, and discuss the likely impact that expression profiling will have on clinical oncology.

Entities:  

Mesh:

Year:  2002        PMID: 11919254     DOI: 10.1200/JCO.2002.20.7.1932

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  53 in total

1.  Transcriptional gene expression profiles of HGF/SF-met signaling pathway in colorectal carcinoma.

Authors:  Xue-Nong Li; Yan-Qing Ding; Guo-Bing Liu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

2.  Assessment of reliability of microarray data and estimation of signal thresholds using mixture modeling.

Authors:  Musa H Asyali; Mohamed M Shoukri; Omer Demirkaya; Khalid S A Khabar
Journal:  Nucleic Acids Res       Date:  2004-04-27       Impact factor: 16.971

Review 3.  Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.

Authors:  Roberta Russo; Mario Capasso; Paolo Paolucci; Achille Iolascon
Journal:  Eur J Clin Pharmacol       Date:  2010-11-11       Impact factor: 2.953

4.  Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin.

Authors:  M Heishi; J Ichihara; R Teramoto; Y Itakura; K Hayashi; H Ishikawa; H Gomi; J Sakai; M Kanaoka; M Taiji; T Kimura
Journal:  Diabetologia       Date:  2006-05-23       Impact factor: 10.122

Review 5.  Gene expression profiling of primary breast cancer.

Authors:  Roman Rouzier; Peter Wagner; Paolo Morandi; Lajos Pusztai
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

6.  History of the Baylor Charles A. Sammons Cancer Center.

Authors:  Marvin J Stone; Billie E Aronoff; W Phil Evans; Joseph W Fay; Z H Lieberman; Carolyn M Matthews; George J Race; R Pickett Scruggs; C Allen Stringer
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

7.  Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips.

Authors:  James Stec; Jing Wang; Kevin Coombes; Mark Ayers; Sebastian Hoersch; David L Gold; Jeffrey S Ross; Kenneth R Hess; Stephen Tirrell; Gerald Linette; Gabriel N Hortobagyi; W Fraser Symmans; Lajos Pusztai
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

8.  Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative.

Authors:  Dondapati Chowdary; Jessica Lathrop; Joanne Skelton; Kathleen Curtin; Thomas Briggs; Yi Zhang; Jack Yu; Yixin Wang; Abhijit Mazumder
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

9.  Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer.

Authors:  Antonio Isidoro; Marta Martínez; Pedro L Fernández; Alvaro D Ortega; Gema Santamaría; Margarita Chamorro; John C Reed; José M Cuezva
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

Review 10.  Genomic markers for decision making: what is preventing us from using markers?

Authors:  Vicky M Coyle; Patrick G Johnston
Journal:  Nat Rev Clin Oncol       Date:  2009-12-15       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.